Haloperidol Rompharm (Haloperidol)

Haloperidol Rompharm is indicated for several psychiatric conditions where dopamine blockade is therapeutic. The medication may be prescribed as part of a comprehensive treatment plan that includes psychosocial interventions.

• Schizophrenia, including acute exacerbations.
• Acute psychotic episodes associated with mood disorders.
• Tourette syndrome and other tic disorders.
• Severe agitation or aggression when rapid control is required.
• Adjunctive treatment for hyperkinetic movement disorders.
• Maintenance therapy to prevent relapse after stabilization of psychotic symptoms.

Side effects of Haloperidol Rompharm vary in frequency and severity, reflecting its dopamine antagonism.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary facial movements.
• Significant cardiac arrhythmias, including QT prolongation.

Clinicians should evaluate patient history and monitor for specific risks before and during treatment with Haloperidol Rompharm.

• History of cardiovascular disease or prolonged QT interval.
• Pre‑existing movement disorders or Parkinsonian symptoms.
• Severe hepatic or renal impairment.
• Pregnancy, lactation, or plans for conception.
• Elderly patients, especially those with dementia‑related psychosis.
• Concomitant use of other central nervous system depressants.

Haloperidol Rompharm can interact with several drug classes, potentially altering its efficacy or safety profile.

Avoid

• Other antipsychotics or dopamine antagonists, which may increase extrapyramidal risk.
• Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants including benzodiazepines, opioids, or alcohol.
• Anticholinergic agents that may mask extrapyramidal symptoms.
• CYP2D6 substrates, as haloperidol metabolism may be affected.